Linkage Biosciences Awarded NHS Contract
News Aug 30, 2016
The new tissue typing platform, including Real-Time PCR instrumentation, will be installed and adopted by various laboratories across the country.
Dr. Andrea Harmer, National Head of NHS Blood and Transplant H&I Services, said, “At NHS Blood and Transplant, we were looking for the best technology available for our rapid typing requirements. We developed a comprehensive matrix to evaluate multiple platforms and were extremely pleased with the results from Linkage Biosciences. The laboratory tests performed by our scientists showed the product to be simple to use, fast, and robust.”
“We are excited to partner with NHS Blood and Transplant and support the fast-growing adoption of LinkSēq tissue typing technology,” said Zachary Antovich, Chief Executive Officer of Linkage Biosciences. “The technical advantages of LinkSēq, as supported by all the necessary evidence during the evaluation period, clearly established the superiority of our offering. The decision of the UK’s NHS Blood and Transplant to select our product is the outcome of a thorough evaluation of the competitive landscape and we suspect other nations will view this tender as a benchmark for their own assessment.”
LinkSēq offers a dramatically simplified workflow for detecting Human Leukocyte Antigen (HLA) genes associated with tissue compatibility for organ transplantation. With less than 10 minutes of set-up and no further operator intervention, LinkSēq provides complete molecular genotyping results in as little as 90 minutes. Its simple workflow avoids post-amplification contamination, as well as allowing rapid turnaround time and increased laboratory productivity.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019
4th EuroSciCon Conference on Gynecologic Oncology and Reproductive Disorders
Jul 25 - Jul 26, 2019